Supply of bethanechol chloride (UROCARB) 10 mg tablets by Mayne Pharma International Salisbury

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, is designed to regulate the supply and quality of therapeutic goods to ensure they meet safety, efficacy, and quality standards. This Act was introduced to address the need for a comprehensive framework governing the importation, supply, and quality of therapeutic goods, including medicines, medical devices, and blood and blood components, to protect public health. One of the key mechanisms within the Act is the issuance of consents to supply products that do not fully comply with certain standards, subject to specific conditions to mitigate any potential risks. On April 12, 2013, the delegate of the Secretary of the Department of Health and Ageing exercised this authority by granting consent for the supply of bethanechol chloride (UROCARB) 10 mg tablets, produced by Mayne Pharma International, despite it not meeting the related substances requirements of the USP 2013 monograph. This consent, which was subject to ongoing investigations into developing a compliant test method, reflects the Act's policy objective of balancing public health protection with the need for timely access to therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, with Section 14 and 14A providing specific provisions for the supply of therapeutic goods that do not conform to certain standards or specifications. On April 12, 2013, the delegate of the Secretary of the Department of Health and Ageing granted consent for Mayne Pharma International, based in Salisbury, South Australia, to supply bethanechol chloride (UROCARB) 10 mg tablets [Aust R 14861], which does not conform to the related substances requirements of the USP 2013 monograph for Bethanechol Chloride Tablets and the USP 2013 monograph for Bethanechol Chloride for the drug substance. This consent is subject to conditions outlined in the Act, including the continuation of investigations into developing a test method to ensure compliance with the official standards. This consent applies until the end of July 2013, and no other changes have been made to the product. The Act applies to persons and entities involved in the supply of therapeutic goods in Australia, including manufacturers, importers, and suppliers, and its jurisdictional reach extends across the Commonwealth, with each state and territory also having their own legislation that may further regulate the supply of therapeutic goods within their borders.

Key Provisions

The Therapeutic Goods Act 1989, specifically sections 14 and 14A, provides the framework under which the delegate of the Secretary of the Department of Health and Ageing can grant consent for the supply of therapeutic goods that do not fully comply with specified standards. In this instance, section 14(a) authorises the delegate to permit the supply of bethanechol chloride (UROCARB) 10 mg tablets by Mayne Pharma International, despite the product not meeting the related substances requirements of the USP 2013 monograph for Bethanechol Chloride Tablets and the USP 2013 monograph for Bethanechol Chloride as the drug substance. This consent is granted conditionally under section 15(1), which stipulates that the supply will be allowed only until the end of July 2013. Additionally, it mandates that investigations into developing a test method to ensure compliance with the official standards must continue. The Act imposes several obligations on the parties involved. The delegate of the Secretary must ensure that the consent granted is accompanied by conditions that aim to protect public health and safety. In this case, the conditions include a time-limited consent period and an ongoing commitment to develop a test method for compliance. Mayne Pharma International, the entity supplying the product, must adhere to these conditions and ensure that the product supplied remains within the parameters set by the Act. Furthermore, the company must cooperate with any investigations and provide necessary updates to the delegate to maintain the consent. Failure to comply with the conditions set forth in the consent or any other requirements of the Therapeutic Goods Act 1989 can result in significant legal consequences. While the specific penalties for non-compliance are not detailed in the provided text, the Act generally allows for both civil and criminal penalties. Civil penalties may include fines, while criminal penalties could involve imprisonment, reflecting the seriousness with which the Act treats breaches that compromise public health and safety. The maximum penalties would depend on the specific breach and the extent of the non-compliance.